RETIFANLIMAB-DLWR

72 reported adverse events

Drug classes: Programmed Death Receptor-1 Blocking Antibody [EPC]

These side effects are most commonly reported by patients taking RETIFANLIMAB-DLWR:

# Side effect Count
0 OFF LABEL USE 25
1 DISEASE PROGRESSION 11
2 ANAL SQUAMOUS CELL CARCINOMA 6
3 ANAL CANCER 5
4 DEATH 4
5 MALIGNANT NEOPLASM PROGRESSION 4
6 NAUSEA 4
7 ANAEMIA 3
8 CONDITION AGGRAVATED 3
9 DECREASED APPETITE 3
See all common reactions for RETIFANLIMAB-DLWR

RETIFANLIMAB-DLWR is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ANAL CANCER RECURRENT 1 0.0476
1 ANAL SQUAMOUS CELL CARCINOMA 6 0.0195
2 COLOSTOMY INFECTION 1 0.0167
3 ANAL CANCER 5 0.0052
4 NEUROENDOCRINE CARCINOMA OF THE SKIN 1 0.0010
5 SECONDARY ADRENOCORTICAL INSUFFICIENCY 1 0.0007
6 INFUSION SITE INFECTION 1 0.0004
7 JOINT LOCK 1 0.0004
8 THYROIDITIS 1 0.0003
9 AUTOIMMUNE THYROIDITIS 1 0.0003
See all enriched reactions for RETIFANLIMAB-DLWR